Formulation for the treatment of obesity

Details Formulation for the treatment of obesity Formulation for the treatment of obesity

2007-10-30

2007-10-30

Pryor, Alton (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

Reexamination Certificate

active

10454538

ABSTRACT:
The present invention refers to a formulation for a slimming treatment comprising in certain quantities: hypothalamus powder, hypophysis powder, thyroid powder, suprarenal cortex powder and pancreas powder, and other polyglandular opotherapic extracts such as extract of ovary or testicle; said slimming treatment being evaluated and optimised thanks to an exponential mathematical model which models the accumulated weight loss of a patient by means of a differentiation and separation of the slimming effect due to the set of factors depending on the applied slimming treatment and, on the other hand, of the slimming effect due to the set of factors depending on the typology of the patient trying to slim.

REFERENCES:
Boletin Informativo, 1994, Cento Regional de Farmacovigilancia e Informacion Terapeutica de Canarias, vol. 2 No. 5 pp. 1-4.
Thesis: Sylvie Voisin-Dahan, “Les Substances D'Origine Animale Utilisées en Therapeutique”, Université Paris V. René Descartes, Table of Contents, No. 252, (1987).
José Cabrera Forneiro and Rafael Cabrera Bonel, “Efectos Secundarios y Tóxicos de los Psicofármacos”, Su tratamiento, (ROCHE), pp. 5-22, (1983).
A. del Rio Vázquez et al., “Result of the Administration of High Doses of Bumetanide to Patients With Chronic Renal Failure Who Are On A Program of Hemodialysis”, Medicina Clinica, Vo. 72, No. 25, pp. 70-73, (Jan. 1979).
D.A. Silk, Progress Report, “Peptide Absorption in Man”, Gut, vol. 15, pp. 494-501, (1974).
K.E. Webb, Jr., “Amino Acid and Peptide Absorption from the Gastrointestinal Tract”, Federation Proceedings, vol. 45, No. 8, pp. 2268-2271, (Jul. 1986).
Thesis: Jean-Cleaude Dahan, “Les Substances D'Origine Animale Utilisées en Therapeutique”, Université Paris V René Descartes, No. 251, (1987).
Laboratoire Industriel de Biologie report citing “Hypothalamic Hormones” (Serono Symposia), Academic Press Inc. London, last page, (1975).
Martine Allain-Regnault, “Une nouvelle chimie du cerveau”, La Revue TRIANGLE: Journal Sandoz des Sciences Médicales, deuxieme trimestre, vol. XVI, No. 2, p. 39, (1976).
John A. Owen, Jr., “Focus on bumetanide. An extremely potent diuretic with minimal toxicity”, Hospital Formulary Press, pp. 933-935 (Sep. 1981).
Alastair J. J. Wood, “Use of Benzodiazepines in Anxiety Disorders”, The New England Journal of Medicine, pp. 1398-1405, (May 13, 1993).
Laboratoire Industriel de Biologie “L'opotherapie”, no date shown.
Institut Français de Recherches et Essais Biologiques, Lot No. 7007, (May 10, 1976).
Archivo Bibliografico del Ilustre Colegio de Medicos de Cordoba, 44-45 (Nov. 1985)—English translation.
Archivo Bibliografico del Ilustre Colegio de Medicos de Cordoba, 44-45 (Nov. 1985).
Spanish System of Drug Control, Informative Bulletin Regional Center of Drug Control and Therapeutic Information of Canary Islands, vol. 2, No. 5, 1994.

Affiliated with

Also associated with

Rating

Formulation for the treatment of obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulation for the treatment of obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation for the treatment of obesity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3898918